Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
SOUTH SAN FRANCISCO, Calif., Nov. 29, 2016 -- Fluidigm Corporation (NASDAQ:FLDM) today announced that it will webcast the company’s presentation at the Piper Jaffray 28th Annual Healthcare Conference in New York City on November 30, 2016. Chris Linthwaite, President and Chief Executive Officer, will participate in a 25-minute question-and-answer session scheduled to begin at 12:30 PM ET.
The webcast can be accessed at: http://edge.media-server.com/m/p/2zv6dc6r.
The webcast will be archived for 90 days following the live presentation.
About Fluidigm
Fluidigm (NASDAQ:FLDM) develops, manufactures, and markets life science analytical and preparatory systems for growth markets such as single-cell biology and production genomics. We sell to leading academic institutions, clinical laboratories, and pharmaceutical, biotechnology, and agricultural biotechnology companies worldwide. Our systems are based on proprietary microfluidics and multiparameter mass cytometry technology and are designed to significantly simplify experimental workflow, increase throughput, and reduce costs while providing excellent data quality. Fluidigm products are provided for Research Use Only. Not for use in diagnostic procedures.
We use our website (www.fluidigm.com), corporate Twitter account (@fluidigm), Facebook page (https://www.facebook.com/fluidigm), and LinkedIn page (https://www.linkedin.com/company/fluidigm-corporation) as channels of distribution of information about our products, our planned financial and other announcements, our attendance at upcoming investor and industry conferences, and other matters. Such information may be deemed material information, and we may use these channels to comply with our disclosure obligations under Regulation FD. Therefore, investors should monitor our website and our social media accounts in addition to following our press releases, SEC filings, public conference calls, and webcasts.
Fluidigm and the Fluidigm logo are trademarks or registered trademarks of Fluidigm Corporation.
Contact Fluidigm Corporation Ana Petrovic Director, Corporate Development and Investor Relations 650 243 6628 (office) [email protected]
